Fridays review

Fridays is a telehealth coordinator built around medication plus ongoing support, not simply an online prescription service. The process starts with an eligibility quiz, payment and a detailed health-history intake, followed by clinician review through an affiliated medical practice; depending on state rules, that review can involve a video appointment or an asynchronous prescription-fill process. A clinician can order labs and prescribe only when appropriate, so payment does not guarantee medication. The advertised package includes provider visits, prescription management, group sessions covering nutrition, movement and mental health, one-on-one dietitian and journey-support coaching, and the SESH fitness app. Early clinical check-ins are usually monthly. Required testing commonly includes a metabolic panel, A1C, thyroid test and lipid panel; testing at Quest is advertised as included, while using another laboratory can create an extra expense.

This structure fits someone who wants more accountability than a medication-only service and is comfortable receiving care through Fridays’ network of independent clinicians, laboratories and partner pharmacies. It is especially relevant to self-pay shoppers considering a compounded product, because medication, coaching and clinical access are presented as one bundled charge. It is a poor fit for anyone who wants a guaranteed prescription, a specific brand or pharmacy before enrolling, or a clean month-to-month price without promotional math. Insurance does not cover the program’s virtual visits, according to the company, although its team provides prior-authorization and appeals support for branded prescriptions. Actual brand-name cost still depends on coverage, deductibles and pharmacy benefits.

The cost page deserves scrutiny. As of July 2026, its main summer promotion advertises compounded semaglutide from $117 per month with code NYNY12 and compounded tirzepatide from $198 per month with code NEWYOU12, both presented alongside 12-month savings. Yet the same page also displays older-looking figures of $150 per month when paid annually or $249 month to month for semaglutide, and $240 per month when paid annually or $359 month to month for tirzepatide. As of July 2026, it separately lists self-pay Ozempic at $1,498 per month and Zepbound at $1,828 per month, while its Wegovy routes advertise a $49 first-month membership with medication excluded, followed by membership as low as $98 per month on a prepaid annual plan. The compounded packages say membership, medication and Quest labs are included, but the duplicated and conflicting price blocks prevent a dependable total from being calculated from the public page alone. The terms also allow promotional rates to roll into the then-current recurring price and require cancellation at least 72 hours before renewal.

The medication path includes compounded semaglutide or tirzepatide as well as branded options. That choice carries a real verification burden: compounded drugs are not FDA-approved and do not receive FDA premarket review for safety, effectiveness or quality. FDA also reports dosing errors with compounded injections and warns that semaglutide sodium and semaglutide acetate are different active ingredients from the base form used in approved products. Fridays says it does not manufacture the drugs and lists several partner pharmacies, but the dispensing pharmacy and exact formulation can depend on the prescription, location and fulfillment route. Before paying, the buyer still needs checkout to reveal the actual upfront charge, whether the offer requires full annual prepayment, how long the discount lasts, the renewal amount, state availability and any brand-name medication cost after insurance. The prescription, product form, concentration, added ingredients, dispensing pharmacy and delivery schedule also remain unresolved until clinical review and fulfillment.

Use this sequence before entering payment details. It keeps program marketing, eligibility review and final billing terms separate.

Fridays pricing pages show promotional monthly prices for compounded semaglutide and tirzepatide, while its weight-loss page describes a broader GLP-1 program with dietitian support, fitness features and community. Those features can be useful, but they should be separated from the medication decision.

Fridays mentions both brand-name and compounded medication pathways. FDA-approved Wegovy and Zepbound have labels, manufacturing controls and specific approved uses. Compounded products may be legally prescribed in some circumstances, but they are not FDA-approved. The user experience can look similar online, so the verification step matters.

Fridays may appeal to users who want a lower advertised cash-pay route and lifestyle support in the same program. It may be less ideal for users who want a conservative brand-name-only pathway or who dislike promotional terms that require careful reading.

Fridays shows some of the more aggressive public promotional pricing in this category. Its pricing page lists compounded semaglutide and tirzepatide offers with visible monthly figures, promo-code savings and plan-length language. That makes it useful for price discovery, but it also means the review must distinguish the promotional price, the annual-plan price, the month-to-month price and the product type. A user comparing Fridays with Ro or Hims should not compare a compounded promo against a branded medication price as if the products were identical. The fair comparison is total monthly cost for the exact plan length and exact medication route.

Fridays markets lifestyle coaching, nutrition and mental-health coaching, support groups, prescription ordering and provider visits. Those services can be useful if the patient actually uses them. They also make the provider harder to compare against medication-only offers because part of the price is a support program. The review should therefore ask whether the support is synchronous or self-serve, whether dietitian access is one-on-one, how often provider visits are available, and how users get help when side effects or dose questions come up. A low medication price is less valuable if the care path is unclear.

Fridays uses both brand-name and compounded language. That is not unusual in 2026 telehealth weight loss, but it creates a responsibility to explain product differences plainly. FDA-approved products such as Wegovy and Zepbound have approved labels, manufacturing oversight and specific indications. Compounded products are not FDA-approved and FDA has warned telehealth companies not to market compounded GLP-1s as generic versions or as clinically proven equivalents to the approved drugs. A user can still discuss compounded options with a clinician, but the review should not blur the two categories.

Fridays is a provider where the checkout details can change the entire value judgment. A user should compare the price with and without the promo code, the annual-plan price versus month-to-month, and the cost after the first renewal. If the plan includes coaching, dietitian support or support groups, ask whether those services are unlimited, scheduled or promotional. The other major comparison is tolerability. A long discounted plan may look attractive, but GLP-1 side effects, dose adjustments or non-eligibility can change the value quickly. The safest approach is to understand refund rules before choosing a longer commitment.

Fridays may be a good fit for price-sensitive users who want a broader support program and are comfortable verifying promo terms. It is less ideal for users who want conservative brand-only treatment or who dislike annual commitments. The page should be approached like a deal page plus a medical program: the deal can be real, but the medical, pharmacy and renewal details still decide whether it is a good decision. Compare Fridays against Mochi for compounded cash-pay care and against Ro or LifeMD if insurance-supported branded medication is more important.